Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Priaxon AG
DescriptionSmall molecule antagonist of MDM2/p53 protein-protein interaction
Molecular Target Mdm2 p53 binding protein homolog (MDM2) (HDM2)
Mechanism of ActionMdm2 p53 binding protein homolog (MDM2) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsReduction of side-effects caused by radiation or chemotherapy
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today